Loading clinical trials...
Loading clinical trials...
Open Label, Single-arm, Phase IIIb Clinical Trial to Evaluate the Safety of Switching From Intravenous Rituximab to Subcutaneous Rituximab During First Line Treatment for CD20+ Non-Hodgkin's Follicular Lymphoma and Diffuse Large B-cell Lymphoma.
Conditions
Interventions
Rituximab
Locations
39
Spain
Hospital De Txagorritxu; Servicio de Hematologia
Vitoria-Gasteiz, Alava, Spain
Hospital General de Elda; Servicio de Hematologia
Elda, Alicante, Spain
Hospital Son Llatzer; Servicio de Hematologia
Palma de Mallorca, Balearic Islands, Spain
Hospital de Granollers, Servicio de Hematología
Granollers, Barcelona, Spain
Hospital Mutua de Terrassa; Servicio de Hematologia
Terrassa, Barcelona, Spain
Hospital General de Castellon; Servicio de Hematologia
Castellon, Castellon, Spain
Start Date
November 11, 2013
Primary Completion Date
April 11, 2017
Completion Date
April 11, 2017
Last Updated
December 26, 2018
Lead Sponsor
Hoffmann-La Roche
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions